US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

0.2810 -0.0016 (-0.57%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vistagen Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
BioMedNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases Q1 2025 Financial, Corporate Report
Via Investor Brand Network
News headline image
VTGN Stock Earnings: VistaGen Therapeutics Beats EPS, Misses Revenue for Q1 2025 ↗
VTGN stock results show that VistaGen Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2025. 
Via InvestorPlace
News headline image
Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update
From Vistagen
Via Business Wire
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q1 2025 Results, Conference Call
Via Investor Brand Network
News headline image
Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024
From Vistagen
Via Business Wire
News headline image
3 Stocks Under $15 That Could Make You a Millionaire ↗
Investors looking for millionaire status in the coming years should consider three stocks under $15 that could be worth buying. 
Via InvestorPlace
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Awarded New Patents from Four Countries to Broaden Global PH80 IP Portfolio
Via Investor Brand Network
Topics Intellectual Property
News headline image
Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine
From Vistagen
Via Business Wire
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Receives Mental Health America’s Highest Honor
Via Investor Brand Network
News headline image
Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year
From Vistagen
Via Business Wire
TinyGemsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases FY 2024 Financial Report, Corporate Update
Via Investor Brand Network
News headline image
VTGN Stock Earnings: VistaGen Therapeutics Beats EPS, Misses Revenue for Q4 2024 ↗
VTGN stock results show that VistaGen Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024. 
Via InvestorPlace
News headline image
Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
From Vistagen
Via Business Wire
BioMedNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules FY 2024 Financial Results Report, Conference Call
Via Investor Brand Network
News headline image
Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024
From Vistagen
Via Business Wire
TinyGemsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) CEO to Present at Jefferies Global Healthcare Conference
Via Investor Brand Network
News headline image
Vistagen to Present at the Jefferies Global Healthcare Conference
From Vistagen
Via Business Wire
BioMedNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Present Posters at Upcoming ASCP Conference
Via Investor Brand Network
News headline image
Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference
From Vistagen
Via Business Wire
News headline image
3 Must-Have Penny Stocks to Boost Your 2024 Portfolio ↗
Though volatility remains high, these penny stocks promise significant returns, especially in this high-interest rate economic climate. 
Via InvestorPlace
News headline image
Meme Stock Rebound: 3 Reddit Favorites Primed for a Resurgence ↗
The internet and forums such as Reddit, are rife with misinformation about stock prospects. However, these three might have potential. 
Via InvestorPlace
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Present at Upcoming RBC Capital Markets Global Healthcare Conference
Via Investor Brand Network
News headline image
Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference
From Vistagen
Via Business Wire
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Reports Positive PH15 Data from Pilot Study Showing Psychomotor Impairment Improvement
Via Investor Brand Network
News headline image
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
From Vistagen
Via Business Wire
News headline image
7 Stocks Under $15 Predicted to Boom in the Next 2 Years ↗
Discover seven promising stocks priced under $15, leading in sectors like financial services, biotechnology, and energy. 
Via InvestorPlace
News headline image
Millionaire Makers: 3 Stocks Under $10 Set to Skyrocket by 2027 ↗
Explore three stocks under $10 in electronic equipment and instruments, technology hardware, storage and peripherals, and biotechnology. 
Via InvestorPlace
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation at Upcoming Anxiety and Depression Association Conference
Via Investor Brand Network
News headline image
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
From Vistagen
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >